Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
API SUPPLIERS
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Click Us!
TAPI offers customized CDMO Solutions for API development and manufacturing services.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39508
Submission : 2024-02-23
Status :
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
29 Sep 2023
// PR NEWSWIRE
25 May 2023
// BUSINESSWIRE
19 Jan 2023
// PR NEWSWIRE
10 Sep 2022
// BUSINESSWIRE
10 Aug 2022
// BUSINESS WIRE
24 Jan 2022
// BUSINESSWIRE
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]US Patents
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]US Exclusivities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Ripretinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ripretinib, including repackagers and relabelers. The FDA regulates Ripretinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ripretinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ripretinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ripretinib supplier is an individual or a company that provides Ripretinib active pharmaceutical ingredient (API) or Ripretinib finished formulations upon request. The Ripretinib suppliers may include Ripretinib API manufacturers, exporters, distributors and traders.
click here to find a list of Ripretinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ripretinib DMF (Drug Master File) is a document detailing the whole manufacturing process of Ripretinib active pharmaceutical ingredient (API) in detail. Different forms of Ripretinib DMFs exist exist since differing nations have different regulations, such as Ripretinib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ripretinib DMF submitted to regulatory agencies in the US is known as a USDMF. Ripretinib USDMF includes data on Ripretinib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ripretinib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ripretinib suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ripretinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ripretinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ripretinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ripretinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ripretinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ripretinib suppliers with NDC on PharmaCompass.
Ripretinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ripretinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ripretinib GMP manufacturer or Ripretinib GMP API supplier for your needs.
A Ripretinib CoA (Certificate of Analysis) is a formal document that attests to Ripretinib's compliance with Ripretinib specifications and serves as a tool for batch-level quality control.
Ripretinib CoA mostly includes findings from lab analyses of a specific batch. For each Ripretinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ripretinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Ripretinib EP), Ripretinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ripretinib USP).
LOOKING FOR A SUPPLIER?
Share
